CSL Seqirus

News

Sanofi escapes fine in EU mismarketing case

Sanofi will not be fined for disparaging an influenza vaccine sold by rival CSL in a marketing campaign, according to the European Commission.

News

UK first country to launch CSL's trivalent flu shot Aujemflu

CSL Seqirus' recently approved trivalent, cell-based influenza vaccine Aujemflu will be part of the UK's 2027/28 immunisation campaign.

News

EU seeks advice on Sanofi's response to mismarketing claim

The EU is asking for feedback on measures proposed by Sanofi to address concerns about an allegedly misleading marketing campaign for a flu vaccine.

News

Sanofi faces EU investigation over flu shot marketing

The European Commission is investigating a marketing campaign run by Sanofi for a flu vaccine, to see if it disparaged its only rival in the market.

News

Falling flu vaccine sales in US stall CSL's Seqirus spinout

CSL says flu vaccination rates in the US are expected to fall 12% to 14% this year, and have scuppered its plan to spin out its vaccines unit Seqirus.

News

CSL will slash headcount and hive off vaccine business

Facing declines in flu vaccination rates in the US, CSL will spin out its vaccine unit as part of a wider restructuring that will claim 3,000 jobs.

Sanofi escapes fine in EU mismarketing case

UK first country to launch CSL's trivalent flu shot Aujemflu

EU seeks advice on Sanofi's response to mismarketing claim

Sanofi faces EU investigation over flu shot marketing

Falling flu vaccine sales in US stall CSL's Seqirus spinout

CSL will slash headcount and hive off vaccine business

Flagship joins three biotechs together to form Etcelera

Discover a new era of healthcare panel engagement: Grounded ...

CSL Seqirus

Editor's Picks